Additionally, the association is important in driving a future ability to tailor therapy to those who will benefit, and to investigate further the relationship in the context of HLA-DRB1*15 status and TNFR1 polymorphism, to direct treatment to those that will demonstrate maximum benefit, but also to ensure no adverse effects (as demonstrated in MS). This evidence concerns the gene TNFRSF1A and myeloid sarcoma.